{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-cytokine+therapy&page=2", "query": { "intervention": "anti-cytokine therapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 298, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-cytokine+therapy&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-cytokine+therapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T17:31:58.124Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04013672", "title": "Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "SurVaxM", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "Montanide ISA 51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Peereboom", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2020-03-19", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04013672" }, { "nct_id": "NCT02383212", "title": "Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Malignancies" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Hypofractionated radiotherapy", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2015-02-02", "completion_date": "2019-11-18", "has_results": false, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 40, "location_summary": "Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 31 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02383212" }, { "nct_id": "NCT06582017", "title": "Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Pancreas Cancer", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Gastrointestinal Cancer", "Lung Cancer", "Prostate Cancer", "Breast Cancer" ], "interventions": [ { "name": "QXL138AM Injection every 2 weeks by IV Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nammi Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-08-28", "completion_date": "2028-05-30", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 10, "location_summary": "Los Angeles, California • Newport, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06582017" }, { "nct_id": "NCT05011188", "title": "FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "FOR46", "type": "BIOLOGICAL" }, { "name": "Enzalutamide", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Blood Samples", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 44, "start_date": "2022-01-19", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05011188" }, { "nct_id": "NCT05129280", "title": "A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "RO7444973", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2022-01-25", "completion_date": "2023-07-12", "has_results": false, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05129280" }, { "nct_id": "NCT04150562", "title": "Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear-Cell Renal Carcinoma" ], "interventions": [ { "name": "rhIL-15", "type": "DRUG" }, { "name": "Avelumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-05-26", "completion_date": "2021-09-16", "has_results": true, "last_update_posted_date": "2022-05-17", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150562" }, { "nct_id": "NCT00040872", "title": "Multiple Therapies in Treating Patients With Advanced Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "monoclonal antibody 3F8", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "drug resistance inhibition treatment", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "syngeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2013-03-07", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040872" }, { "nct_id": "NCT00110812", "title": "Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2005-09", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 11, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Bethesda, Maryland + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110812" }, { "nct_id": "NCT00490529", "title": "Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Mantle-Cell" ], "interventions": [ { "name": "CpG-MCL vaccine", "type": "BIOLOGICAL" }, { "name": "PF-3512676", "type": "BIOLOGICAL" }, { "name": "Vaccine-primed T-cells", "type": "PROCEDURE" }, { "name": "Autologous hematopoietic stem cell transplant (HSCT)", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Standard induction chemotherapy", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Ronald Levy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 59, "start_date": "2009-08", "completion_date": "2017-12-14", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490529" }, { "nct_id": "NCT04028063", "title": "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Soft Tissue Sarcoma", "Advanced Soft Tissue Sarcoma" ], "interventions": [ { "name": "Balstilimab", "type": "DRUG" }, { "name": "Zalifrelimab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Botensilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 65, "start_date": "2020-01-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-10T17:31:58.124Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028063" } ] }